High-dose albumin for neuroprotection in acute ischemic stroke

From basic investigations to multicenter clinical trial

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Albumin (ALB), the plasma's most abundant protein, is a multifunctional molecule with potent antioxidant and intravascular actions. Albumin is in widespread clinical use to provide circulatory support in the settings of shock, burns, and surgery. More recently, we have shown that albumin when administered in high doses acts as a powerful neuroprotective agent in acute ischemic stroke and brain injury. In experimental studies of focal cerebral ischemia conducted in physiologically monitored rats, animals treated with ALB (typically 25% solution in doses of 1.25 g/kg and above) showed improved neurological score, substantial reductions of infarct volume, and markedly reduced brain swelling compared to saline placebo-treated rats, with a therapeutic window of 4-5 h. In mechanistic studies, ALB improved local blood flow in the ischemic penumbra; antagonized postischemic microvascular thrombosis; improved perfusion distal to microvascular thrombi; and facilitated delivery of fatty acids to the postischemic brain. In a two-center dose-escalation human pilot clinical trial, ALB was generally well tolerated; the chief adverse event was mild-to-moderate pulmonary edema in 13% of subjects, which could be readily managed. A major phase III multicenter clinical efficacy trial-the ALIAS (Albumin in Acute Stroke) Trial-is now underway in the U.S., Canada, and Israel, employing ALB at the 2 g/kg dose shown in experimental studies to be neuroprotective.

Original languageEnglish (US)
Title of host publicationTranslational Stroke Research
Subtitle of host publicationFrom Target Selection to Clinical Trials
PublisherSpringer New York
Pages691-719
Number of pages29
ISBN (Electronic)9781441995308
ISBN (Print)9781441995292
DOIs
StatePublished - Jan 1 2012

Fingerprint

Multicenter Studies
Albumins
Stroke
Clinical Trials
Thrombosis
Brain Edema
Neuroprotective Agents
Pulmonary Edema
Israel
Neuroprotection
Brain Ischemia
Burns
Serum Albumin
Brain Injuries
Canada
Shock
Fatty Acids
Perfusion
Antioxidants
Placebos

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Ginsberg, M. (2012). High-dose albumin for neuroprotection in acute ischemic stroke: From basic investigations to multicenter clinical trial. In Translational Stroke Research: From Target Selection to Clinical Trials (pp. 691-719). Springer New York. https://doi.org/10.1007/978-1-4419-9530-8_34

High-dose albumin for neuroprotection in acute ischemic stroke : From basic investigations to multicenter clinical trial. / Ginsberg, Myron.

Translational Stroke Research: From Target Selection to Clinical Trials. Springer New York, 2012. p. 691-719.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ginsberg, M 2012, High-dose albumin for neuroprotection in acute ischemic stroke: From basic investigations to multicenter clinical trial. in Translational Stroke Research: From Target Selection to Clinical Trials. Springer New York, pp. 691-719. https://doi.org/10.1007/978-1-4419-9530-8_34
Ginsberg M. High-dose albumin for neuroprotection in acute ischemic stroke: From basic investigations to multicenter clinical trial. In Translational Stroke Research: From Target Selection to Clinical Trials. Springer New York. 2012. p. 691-719 https://doi.org/10.1007/978-1-4419-9530-8_34
Ginsberg, Myron. / High-dose albumin for neuroprotection in acute ischemic stroke : From basic investigations to multicenter clinical trial. Translational Stroke Research: From Target Selection to Clinical Trials. Springer New York, 2012. pp. 691-719
@inbook{504dd53a79f8420ba8cf847c969eb8e1,
title = "High-dose albumin for neuroprotection in acute ischemic stroke: From basic investigations to multicenter clinical trial",
abstract = "Albumin (ALB), the plasma's most abundant protein, is a multifunctional molecule with potent antioxidant and intravascular actions. Albumin is in widespread clinical use to provide circulatory support in the settings of shock, burns, and surgery. More recently, we have shown that albumin when administered in high doses acts as a powerful neuroprotective agent in acute ischemic stroke and brain injury. In experimental studies of focal cerebral ischemia conducted in physiologically monitored rats, animals treated with ALB (typically 25{\%} solution in doses of 1.25 g/kg and above) showed improved neurological score, substantial reductions of infarct volume, and markedly reduced brain swelling compared to saline placebo-treated rats, with a therapeutic window of 4-5 h. In mechanistic studies, ALB improved local blood flow in the ischemic penumbra; antagonized postischemic microvascular thrombosis; improved perfusion distal to microvascular thrombi; and facilitated delivery of fatty acids to the postischemic brain. In a two-center dose-escalation human pilot clinical trial, ALB was generally well tolerated; the chief adverse event was mild-to-moderate pulmonary edema in 13{\%} of subjects, which could be readily managed. A major phase III multicenter clinical efficacy trial-the ALIAS (Albumin in Acute Stroke) Trial-is now underway in the U.S., Canada, and Israel, employing ALB at the 2 g/kg dose shown in experimental studies to be neuroprotective.",
author = "Myron Ginsberg",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-1-4419-9530-8_34",
language = "English (US)",
isbn = "9781441995292",
pages = "691--719",
booktitle = "Translational Stroke Research",
publisher = "Springer New York",

}

TY - CHAP

T1 - High-dose albumin for neuroprotection in acute ischemic stroke

T2 - From basic investigations to multicenter clinical trial

AU - Ginsberg, Myron

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Albumin (ALB), the plasma's most abundant protein, is a multifunctional molecule with potent antioxidant and intravascular actions. Albumin is in widespread clinical use to provide circulatory support in the settings of shock, burns, and surgery. More recently, we have shown that albumin when administered in high doses acts as a powerful neuroprotective agent in acute ischemic stroke and brain injury. In experimental studies of focal cerebral ischemia conducted in physiologically monitored rats, animals treated with ALB (typically 25% solution in doses of 1.25 g/kg and above) showed improved neurological score, substantial reductions of infarct volume, and markedly reduced brain swelling compared to saline placebo-treated rats, with a therapeutic window of 4-5 h. In mechanistic studies, ALB improved local blood flow in the ischemic penumbra; antagonized postischemic microvascular thrombosis; improved perfusion distal to microvascular thrombi; and facilitated delivery of fatty acids to the postischemic brain. In a two-center dose-escalation human pilot clinical trial, ALB was generally well tolerated; the chief adverse event was mild-to-moderate pulmonary edema in 13% of subjects, which could be readily managed. A major phase III multicenter clinical efficacy trial-the ALIAS (Albumin in Acute Stroke) Trial-is now underway in the U.S., Canada, and Israel, employing ALB at the 2 g/kg dose shown in experimental studies to be neuroprotective.

AB - Albumin (ALB), the plasma's most abundant protein, is a multifunctional molecule with potent antioxidant and intravascular actions. Albumin is in widespread clinical use to provide circulatory support in the settings of shock, burns, and surgery. More recently, we have shown that albumin when administered in high doses acts as a powerful neuroprotective agent in acute ischemic stroke and brain injury. In experimental studies of focal cerebral ischemia conducted in physiologically monitored rats, animals treated with ALB (typically 25% solution in doses of 1.25 g/kg and above) showed improved neurological score, substantial reductions of infarct volume, and markedly reduced brain swelling compared to saline placebo-treated rats, with a therapeutic window of 4-5 h. In mechanistic studies, ALB improved local blood flow in the ischemic penumbra; antagonized postischemic microvascular thrombosis; improved perfusion distal to microvascular thrombi; and facilitated delivery of fatty acids to the postischemic brain. In a two-center dose-escalation human pilot clinical trial, ALB was generally well tolerated; the chief adverse event was mild-to-moderate pulmonary edema in 13% of subjects, which could be readily managed. A major phase III multicenter clinical efficacy trial-the ALIAS (Albumin in Acute Stroke) Trial-is now underway in the U.S., Canada, and Israel, employing ALB at the 2 g/kg dose shown in experimental studies to be neuroprotective.

UR - http://www.scopus.com/inward/record.url?scp=85027328076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027328076&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-9530-8_34

DO - 10.1007/978-1-4419-9530-8_34

M3 - Chapter

SN - 9781441995292

SP - 691

EP - 719

BT - Translational Stroke Research

PB - Springer New York

ER -